<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>METHOTREXATE </b></p>

<p><b>See also: cytotoxics</b></p>

<p><b>See also: nephrotoxic medications</b></p>

<p><b>From the French ANSM drug interactions document of </b></p>

<p><b>September 2016, pp. 151-152</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>METHOTREXATE</b></p>

<p><b>RxNorm: 6851 </b></p>

<p><b>ATC: </b></p>

<p><b>L01BA01 L04AX03</b></p></td>
<td valign="top"><p><b>ACETYLSALICYLIC ACID</b></p>

<p><b>RxNorm: 1191 </b></p>

<p><b>ATC: </b></p>

<p><b>A01AD05 B01AC06 N02BA01</b></p></td>
<td valign="top"><p>Increase of the toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)</p></td>
<td valign="top"><p>With doses of methotrexate &gt; 20 mg/week</p>

<p><b>Contraindication </b> with acetylsalicylic acid used in anatalgic, antipyretic, or anti-inflammatory doses</p>

<p><b>Precaution for use</b></p>

<p>with anti-coagulating doses of acetylsalicylic acid. Weekly monitoring of the CBC during the first weeks that the substances are administered together. Increased monitoring in the case of change (even slight) of renal function, as well as with older patients </p>

<p>With methotrexate used in doses =&lt; 20 mg/week:</p>

<p><b>Precaution for use</b></p>

<p>with acetylsalicylic acid in analgesic, antipyretic, or anti-inflammatory doses. Weekly monitoring of the CBC during the first weeks of administration of the substances together. Increased monitoring in case of change (even slight) in renal function, as well as with older patients.</p></td>
</tr>

<tr>
<td valign="top"><p><b>METHOTREXATE</b></p>

<p><b>RxNorm: 6851 </b></p>

<p><b>ATC: </b></p>

<p><b>L01BA01 L04AX03</b></p></td>
<td valign="top"><p><b>ACITRETIN</b></p>

<p><b>Rx Norm: 16818 </b></p>

<p><b>ATC: D05BB02</b></p></td>
<td valign="top"><p>Risk of increase of the hepatoxicity of the methotrexate</p></td>
<td valign="top"><p><b>Not recommended</b></p>

<p>If administering these substances together is judged necessary, strengthen liver function testing </p></td>
</tr>

<tr>
<td valign="top"><p><b>METHOTREXATE</b></p>

<p><b>RxNorm: 6851 </b></p>

<p><b>ATC: </b></p>

<p><b>L01BA01 L04AX03</b></p></td>
<td valign="top"><p><b>NON STEROIDAL ANTI-INFLAMMATORY DRUGS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>M01A-002</b></p></td>
<td valign="top"><p>Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).</p></td>
<td valign="top"><p><b>Not recommended</b></p>

<p>--for doses of methotrexate greater than 20mg per week</p>

<p>--with the ketoprofen and the methotrexate in doses greater than 20 mg per week, wait at least 12 hours between stopping the methotrexate and the beginning of the treatment with ketoprofen and the dose of methotrexate</p>

<p><b>Precaution for use</b></p>

<p>--with the methotrexate used in week doses (lower than or equal to 20 mg per week), weekly testing of the CBC during the first weeks of the administration of these medications together. Increased monitoring in case of alteration (even slight) of the renal function, as well as with the older patient. </p></td>
</tr>

<tr>
<td valign="top"><p><b>METHOTREXATE</b></p>

<p><b>RxNorm: 6851 </b></p>

<p><b>ATC: </b></p>

<p><b>L01BA01 L04AX03</b></p></td>
<td valign="top"><p><b>PROTON PUMP INHIBITORS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>A02BC-001</b></p></td>
<td valign="top"><p>Risk of increase of the toxicity of the methotrexate due to decrease of its elimination</p></td>
<td valign="top"><p><b>Not recommended</b></p>

<p><b>--</b>with the methotrexate in doses &gt; 20mg /week</p>

<p><b>Take into account</b></p>

<p>--for lower doses</p></td>
</tr>

<tr>
<td valign="top"><p><b>METHOTREXATE</b></p>

<p><b>RxNorm: 6851 </b></p>

<p><b>ATC: </b></p>

<p><b>L01BA01 L04AX03</b></p></td>
<td valign="top"><p><b>CICLOSPORIN</b></p>

<p><b>RxNorm: 3008 </b></p>

<p><b>ATC: </b></p>

<p><b>L04AD01 S01XA18</b></p></td>
<td valign="top"><p>Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.</p></td>
</tr>

<tr>
<td valign="top"><p><b>METHOTREXATE</b></p>

<p><b>RxNorm: 6851 </b></p>

<p><b>ATC: </b></p>

<p><b>L01BA01 L04AX03</b></p></td>
<td valign="top"><p><b>CIPROFLOXACIN</b></p>

<p><b>RxNorm: 2551</b></p>

<p><b>ATC:</b></p>

<p><b>J01MA02 S01AE03 S02AA15 S03AA07</b></p></td>
<td valign="top"><p>Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>METHOTREXATE</b></p>

<p><b>RxNorm: 6851 </b></p>

<p><b>ATC: </b></p>

<p><b>L01BA01 L04AX03</b></p></td>
<td valign="top"><p><b>PENICILLINS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>J01C</b></p></td>
<td valign="top"><p>Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>METHOTREXATE</b></p>

<p><b>RxNorm: 6851 </b></p>

<p><b>ATC: </b></p>

<p><b>L01BA01 L04AX03</b></p></td>
<td valign="top"><p><b>PROBENECID</b></p>

<p><b>RxNorm: 8698</b></p>

<p><b>ATC: M04AB01</b></p></td>
<td valign="top"><p>Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>METHOTREXATE</b></p>

<p><b>RxNorm: 6851 </b></p>

<p><b>ATC: </b></p>

<p><b>L01BA01 L04AX03</b></p></td>
<td valign="top"><p><b>ANTIBACTERIAL SULFONAMIDES</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>JO1E</b></p></td>
<td valign="top"><p>Increase of the hematological toxicity of the methotrexate</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the administration of the substances together and after it is stopped<b>. </b></p></td>
</tr>

<tr>
<td valign="top"><p><b>METHOTREXATE</b></p>

<p><b>RxNorm: 6851 </b></p>

<p><b>ATC: </b></p>

<p><b>L01BA01 L04AX03</b></p></td>
<td valign="top"><p><b>TRIMETHOPRIM</b></p>

<p><b>RxNorm: 10829</b></p>

<p><b>ATC: J01EA01</b></p></td>
<td valign="top"><p>Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

</tbody>
</table>

